GLP-1 users are splurging more on healthy groceries, expensive lean meats, and high-end fitness memberships.|Chemist4U|CC BY-SA 2.0
Weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound aren’t just transforming the waistline, they’re shifting consumer spending.
As these medications reduce food cravings, users are avoiding fast food, confectionery, and snacks.
Those who take GLP-1 also opt to splurge more on healthy groceries, expensive lean meats, and high-end fitness memberships.
Currently, around 16 million Americans (6% of US adults) are on these GLP-1 medications.
Economists at Goldman Sachs predict that with 60 million projected users by 2028, the US GDP could see a 1% jump through their evolving shopping habits.
Ripple effects
An analysis by research firm Grocery Doppio shows fast food and snack industries are taking a hit while other food categories are thriving.
- Snack and confectionery sales dropped 52%. However, baked goods sales fell 47% in early 2024 compared to the same period in 2023.
- Lean meats and fresh produce sales rose by 27% and 13%, respectively, as consumers prioritized quality over quantity.
The fitness industry is also benefitting. According to PwC, 35% of weight-loss drug users are exercising more, and 16% have hired personal trainers for the first time.
Retailers and food brands are already adapting to a consumer base that eats less but spends more on quality.